在高危重度卵巢过度刺激综合征患者中,卵母细胞成熟率是否与用于触发最终卵母细胞成熟的曲普瑞林剂量相关?
本回顾性研究纳入2015年11月至2017年7月间131例高危重度OHSS并接受ICSI的患者,比较0.1 mg(n=42)、0.2 mg(n=46)和0.4 mg(n=43)曲普瑞林触发最终卵母细胞成熟的卵母细胞成熟率。结果显示三组卵母细胞成熟率无显著差异[82.6%(17.8%)vs 83.3%(18.8%)vs 85.1%(17.2%),P=0.686]。
要点
- 0.1 mg曲普瑞林组的卵母细胞成熟率与0.2 mg和0.4 mg组相似。
- 三组间成熟(MII)卵母细胞数、获卵数、受精率等均无显著差异。
- 三组间触发后各时间点LH、FSH、E2和PRG血清水平均无显著差异。
核心结论
- 在高危重度OHSS接受ICSI的患者中,与最常用的0.2 mg剂量相比,使用较低剂量(0.1 mg)或较高剂量(0.4 mg)曲普瑞林触发最终卵母细胞成熟,在卵母细胞成熟率方面未带来任何获益。
研究设计与样本
- 回顾性研究,于2015年11月至2017年7月纳入131例高危重度OHSS并接受卵巢刺激行ICSI的不孕患者。
- 高危重度OHSS定义为触发最终卵母细胞成熟当日存在至少19个直径≥11 mm的卵泡。
- 卵巢刺激采用重组FSH和GnRH拮抗剂,患者分别接受0.1 mg(n=42)、0.2 mg(n=46)或0.4 mg(n=43)曲普瑞林触发最终卵母细胞成熟。
主要发现
- 三组患者基线特征无显著差异。
- 主要结局卵母细胞成熟率在三组间无差异[0.1 mg组82.6%(17.8%)vs 0.2 mg组83.3%(18.8%)vs 0.4 mg组85.1%(17.2%),P=0.686]。
- 成熟(MII)卵母细胞数[0.1 mg组21(13)vs 0.2 mg组20(6)vs 0.4 mg组20(11),P=0.582]、获卵数[25.5(13)vs 24.5(11)vs 23(12),P=0.452]、获卵率[81.0%(17.7%)vs 76.5%(23.5%)vs 75.0%(22.5%),P=0.088]在三组间均无显著差异。
- 受精(双原核)卵母细胞数[12.5(9)vs 14.5(7)vs 14.0(8),P=0.985]、受精率[71.7%(22%)vs 77.1%(19.1%)vs 76.6%(23.3%),P=0.525]及黄体期持续时间[7(1)vs 8(2)vs 7(1)天,P=0.632]在三组间均无显著差异。
- 触发最终卵母细胞成熟后各评估时间点,三组间LH、FSH、E2和PRG血清水平均无显著差异。
临床怎么用
- 基于本研究结果,在高危重度OHSS患者中,与最常用的0.2 mg剂量相比,使用较低剂量(0.1 mg)或较高剂量(0.4 mg)曲普瑞林触发最终卵母细胞成熟,在卵母细胞成熟率方面未带来任何获益。
局限性
- 本研究为回顾性研究,尽管所比较的三组基线特征无差异,但不能排除偏倚的存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are oocyte maturation rates different among 0.1, 0.2 and 0.4 mg triptorelin used for triggering final oocyte maturation in patients at high risk for ovarian hyperstimulation syndrome (OHSS) undergoing ICSI? SUMMARY ANSWER: A dose of 0.1 mg triptorelin results in similar oocyte maturation rates compared to higher doses of 0.2 and 0.4 mg in patients at high risk for OHSS undergoing ICSI. WHAT IS KNOWN ALREADY: The GnRH agonist triptorelin is widely used instead of hCG for triggering final oocyte maturation, in order to eliminate the risk of severe OHSS in patients undergoing ovarian stimulation for IVF/ICSI. However, limited data are currently available regarding its optimal dose use for this purpose in patients at high risk for OHSS. STUDY DESIGN, SIZE, DURATION: A retrospective study was performed between November 2015 and July 2017 in 131 infertile patients at high risk for severe OHSS undergoing ovarian stimulation for ICSI. High risk for severe OHSS was defined as the presence of at least 19 follicles ≥11 mm in diameter on the day of triggering final oocyte maturation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovarian stimulation was performed with recombinant FSH and GnRH antagonists. Patients received 0.1 (n = 42), 0.2 (n = 46) or 0.4 mg (n = 43) triptorelin for triggering final oocyte maturation. Hormonal evaluation of FSH, LH, estradiol (E2) and progesterone (PRG) was carried out on the day of triggering final oocyte maturation, 8 and 36 hours post triggering and 3, 5, 7, and 10 days after triptorelin administration. During this period, all patients were assessed for symptoms and signs indicative of severe OHSS development. Primary outcome measure was oocyte maturation rate, defined as the number of metaphase II (MII) oocytes divided by the number of cumulus-oocyte-complexes retrieved per patient. Results are expressed as median (interquartile range). MAIN RESULTS AND THE ROLE OF CHANCE: No significant differences in patient baseline characteristics were observed among the 0.1 mg, the 0.2 mg and the 0.4 mg groups. Regarding the primary outcome measure, no differences were observed in oocyte maturation rate among the three groups compared [82.6% (17.8%) versus 83.3% (18.8%) versus 85.1% (17.2%), respectively, P = 0.686].In addition, no significant differences were present among the 0.1 mg, 0.2 mg and 0.4 mg groups, regarding the number of mature (MII) oocytes [21 (13) versus 20 (6) versus 20 (11), respectively; P = 0.582], the number of oocytes retrieved [25.5 (13) versus 24.5 (11) versus 23 (12), respectively; P = 0.452], oocyte retrieval rate [81.0% (17.7%) versus 76.5% (23.5%) versus 75.0% (22.5), respectively; P = 0.088], the number of fertilized (two pronuclei) oocytes [12.5 (9) versus 14.5 (7) versus 14.0 (8), respectively; P = 0.985], fertilization rate [71.7% (22%) versus 77.1% (19.1%) versus 76.6% (23.3%), respectively; P = 0.525] and duration of luteal phase [7 (1) versus 8 (2) versus 7 (1) days, respectively; P = 0.632]. Moreover, no significant differences were present among the three triptorelin groups regarding serum levels of LH, FSH, E2 and PRG at any of the time points assessed following triggering of final oocyte maturation. LIMITATIONS, REASONS FOR CAUTION: This is a retrospective study, and although there were no differences in the baseline characteristics of the three groups compared, the presence of bias cannot be excluded. WIDER IMPLICATIONS OF THE FINDINGS: Based on the results of the current study, it appears that triggering final oocyte maturation with a lower (0.1 mg) or a higher dose (0.4 mg) of triptorelin, as compared to the most commonly used dose of 0.2 mg, does not confer any benefit in terms of oocyte maturation rate in patients at high risk for severe OHSS. STUDY FUNDING/COMPETING INTEREST(S): No external funding was obtained for this study. There are no conflicts of interest.
引用
- Lainas GT, Lainas TG, Sfontouris IA, et al. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome? Hum Reprod. 2019. PMID: 31384921. doi:10.1093/humrep/dez105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。